International Journal of Medical Science and Pharmaceutical Research

Background: The injunctive potential of circulating microRNAs (miRNAs) has raised intense investigation for their use as noninvasive biomarkers for liver diseases, especially for hepatitis C (HC). Objective: To determine the diagnostic accuracy of circulating miR-16 and miR-885 in acute hepatitis C (AHC) patients compared with healthy controls. 

Methods: A case–control study was carried out among 120 confirmed cases of acute hepatitis C to compare them with 40 age- and sex-matched healthy controls at Al-Najaf Teaching Hospital, Najaf, Iraq, from March 2024 to February 2025. Concentrations of liver enzymes (ALT, AST, ALP) and C-reactive protein (CRP) in serum were measured using standard biochemical assays, and circulating miR-16 and miR-885 concentrations were measured by quantitative real-time PCR (qRT-PCR). 

Results: miR-16 and miR-885 were significantly increased in patients with HC compared to controls (p < 0.001). Compared with miR-16, miR-885 had a higher r value and significance as a positive correlation with ALT (r = 0.71, p < 0.001) and CRP (r = 0.68, p < 0.001). ROC analysis showed good diagnostic accuracy for both biomarkers: the area under the curve (AUC) was 0.798 (p = 0.03) for miR-16 and 0.885 (p < 0.02) for miR-885. Using cut-off points of 1.85 and 2.10 for high/low miR levels, miR-16 had 82.5% sensitivity and 76% specificity, while miR-885 had 88.3% sensitivity and 82.5% specificity. 

Conclusion: miR-16 and miR-885 are significantly elevated in acute hepatitis C and correlate strongly with biochemical markers of hepatic injury and inflammation. Notably, miR-885 reflects an excellent accuracy in diagnosis which may provide evidence for our results to support the use of miR-885 as a non-invasive biomarker suitable for the early diagnosis and clinical monitoring of HCV infection.

Circulatory microRNAs, miR-16, miR-885, Acute Hepatitis C.

1. Ariyachet, C., Nokkeaw, A., & Tangkijvanich, P. (2025). MicroRNA-885-5p regulates cell cycle progression in liver cancer cells. International Journal of Molecular Medicine, 56(5), 167. https://doi.org/10.3892/ijmm.2025.5608
2. Bandiera, S., Pernot, S., El Saghire, H., Durand, S. C., Thumann, C., Crouchet, E., Ye, T., Fofana, I., Oudot, M. A., Barths, J., Schuster, C., Pessaux, P., Heim, M. H., Baumert, T. F., & Zeisel, M. B. (2016). Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis. Journal of virology, 90(14), 6387–6400. https://doi.org/10.1128/JVI.00619-16 
3. Fang, Y., Yan, D., Wang, L., Zhang, J., & He, Q. (2022). Circulating microRNAs (miR-16, miR-22, miR-122) expression and early diagnosis of hepatocellular carcinoma. Journal of clinical laboratory analysis, 36(7), e24541. https://doi.org/10.1002/jcla.24541 
4. Fasano, M., Ieva, F., Ciarallo, M., Caccianotti, B., & Santantonio, T. A. (2024). Acute Hepatitis C: Current Status and Future Perspectives. Viruses, 16(11), 1739. https://doi.org/10.3390/v16111739
5. Gui, J., Tian, Y., Wen, X., Zhang, W., Zhang, P., Gao, J., Run, W., Tian, L., Jia, X., & Gao, Y. (2011). Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clinical science (London, England : 1979), 120(5), 183–193. https://doi.org/10.1042/CS20100297
6. Huang, Y., Chen, Y., Tu, S., Zhang, J., Qiu, Y., & Yu, W. (2022). Diagnostic accuracy of circulating microRNAs for hepatitis C virus‐associated hepatocellular carcinoma: A systematic review and meta‐analysis. BMC Infectious Diseases, 22, 323. https://doi.org/10.1186/s12879-022-07292-8
7. Joshi, N., Chandane Tak, M., & Mukherjee, A. (2022). The involvement of microRNAs in HCV and HIV infection. Therapeutic Advances in Vaccines and Immunotherapy, 10, 1-15. https://doi.org/10.1177/25151355221106104
8. Krupa, R., et al. (2021). MicroRNA profile and iron-related gene expression in hepatitis Krupa, R., Malecki, W., Czarny, P., Strycharz, J., Jablkowski, M., Kordek, R., Szemraj, J., & Sliwinski, T. (2019). MicroRNA profile and iron-related gene expression in hepatitis C-related hepatocellular carcinoma: a preliminary study. Archives of medical science : AMS, 17(5), 1175–1183. https://doi.org/10.5114/aoms.2019.86613
9. Li, H.-C., et al. (2022). Roles of microRNAs in hepatitis C virus replication and pathogenesis. Viruses, 14(8), 1776. https://doi.org/10.3390/v14081776 
10. Manzoor, S., Malik, I. R., Jahan, S., Sarwar, M. B., Bashir, A., Shams, S., & Hussain, A. (2023). Serum MicroRNAs as Predictors for HCV Progression and Response to Treatment in Pakistani Patients. Genes, 14(2), 441. https://doi.org/10.3390/genes14020441
11. McGowan, K., Simpson, K. J., & Petrik, J. (2020). Expression Profiles of Exosomal MicroRNAs from HEV- and HCV-Infected Blood Donors and Patients: A Pilot Study. Viruses, 12(8), 833. https://doi.org/10.3390/v12080833 
12. Mokhtari, F., Mohebbi, S. R., Sharifian, A., Ramandi, M., & Razzaghi, M. R. (2021). Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases. Gastroenterology and hepatology from bed to bench, 14(Suppl1), S10–S23 
13. Nasser, M. Z., Zayed, N. A., Mohamed, A. M., Attia, D., Esmat, G., & Khairy, A. (2019). Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab Journal of Gastroenterology, 20, 198–204. https://doi.org/10.1016/j.ajg.2019.11.003 
14. Shrivastava, S., Steele, R., Ray, R., & Ray, R. B. (2015). MicroRNAs: Role in Hepatitis C Virus pathogenesis. Genes & diseases, 2(1), 35–45. https://doi.org/10.1016/j.gendis.2015.01.001 
15. Woo, J. (2024). Biomarkers in detection of hepatitis C virus infection. Pathogens, 13(4), 331. https://doi.org/10.3390/pathogens1304033
16. Zhu, B., Wei, X. X., Wang, T. B., Zhou, Y. C., Liu, A. M., & Zhang, G. W. (2015). Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7. Archives of virology, 160(8), 2043–2050. https://doi.org/10.1007/s00705-015-2474-3